The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC).
 
Andrea Wang-Gillam
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Jacobio; Merrimack; Vicus Therapeutics
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CTI (Inst); EMD Serono (Inst); Halozyme (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); pfizer (Inst); Plexxikon (Inst); Precision Therapeutics (Inst); Roche (Inst); Verastem (Inst); Xcovery (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - 3DMedcare (I); Agios (I); Alignmed (I); Amgen (I); Antengene (I); Aptus Clinical; Aptus Clinical (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); BeiGene (I); BiolineRx; Boston Scientific (I); Bridgebio (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CARsgen Therapeutics (I); CASI Pharmaceuticals (I); CASI Pharmaceuticals (I); Celgene; Celgene (I); Celsion (I); Cipla (I); CytomX Therapeutics; Daiichi Sankyo (I); Debiopharm Group (I); Delcath Systems (I); Eisai (I); Exelixis (I); Genoscience Pharma (I); Gilead Sciences; Halozyme; Halozyme (I); Hengrui Medicine (I); Inovio Pharmaceuticals (I); Ipsen (I); Janssen; Jazz Pharmaceuticals (I); Kyowa Hakko Kirin (I); LAM Therapeutics (I); Lilly (I); Loxo; Merck (I); Merrimack; Minapharma (I); Newlink Genetics; Novella Clinical (I); Onxeo (I); PCI Biotech (I); Pfizer; Pharmacyclics; Pharmacyte Biotech; Pieris Pharmaceuticals; QED Therapeutics (I); RedHill Biopharma (I); Sanofi; Sanofi (I); Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); SOBI; Targovax; Tekmira (I); twoXAR; twoXAR (I); VAXIMM; Vicus Therapeutics (I); Yakult Pharmaceutical (I); Yakult Pharmaceutical (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Mabvax (Inst); OncoQuest (Inst); OncoQuest (Inst); Roche (Inst)
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Incyte (Inst); Ipsen (Inst); Jacobio (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pieris Pharmaceuticals (Inst); Sanofi (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); TRACON Pharma (Inst); Tyrogenex (Inst)
 
Zev A. Wainberg
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Five Prime Therapeutics; Genentech; Lilly; Merck; Merck KGaA; Novartis; Sirtex Medical
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech
 
Erkut Hasan Borazanci
Consulting or Advisory Role - Biogen (I); Fujifilm; Genzyme (I); Ipsen; Novartis (I); Teva (I)
Speakers' Bureau - Biogen (I); Genzyme (I); Ipsen; Novartis (I); Taiho Pharmaceutical; Teva (I)
Research Funding - Ambry Genetics (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Idera (Inst); Lilly (Inst); MabVax (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst); Samumed (Inst)
 
Nathan Bahary
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene
Research Funding - Newlink Genetics
 
Mark H. O'Hara
Consulting or Advisory Role - Karyopharm Therapeutics
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Gregory Lawrence Beatty
Stock and Other Ownership Interests - Advaxis; Johnson & Johnson
Honoraria - Incyte; Janssen
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; AstraZeneca; BiolineRx; Bristol-Myers Squibb; Genmab; Incyte; Merck; Opsona Therapeutics; Seagen; Vaccinex
Research Funding - Biothera; Bristol-Myers Squibb; Halozyme; Incyte; Janssen; Newlink Genetics; Novartis; Verastem
Patents, Royalties, Other Intellectual Property - Inventor of intellectual property related to mesothelin CAR T cells that is licensed by the University of Pennsylvania to Novartis.
 
Shubham Pant
No Relationships to Disclose
 
Deirdre Jill Cohen
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Sharp & Dohme; Taiho Pharmaceutical; Vicus Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst)
 
Stephen Leong
Stock and Other Ownership Interests - Amarin Corporation; Antares Pharmaceuticals; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb (Inst); Deciphera (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst)
 
Muhammad Shaalan Beg
Consulting or Advisory Role - Boston Biomedical; Celgene; Genentech/Roche; Guardant Health; Ipsen
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche; Ipsen
Research Funding - Agios (Inst); ArQule (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); MedImmune (Inst); Merck Serono (Inst); Sillajen (Inst); Tolero Pharmaceuticals (Inst)
 
Kenneth H. Yu
Consulting or Advisory Role - celgene; Merck Serono; Merrimack
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene
Speakers' Bureau - Bristol-Myers Squibb; Celgene
Research Funding - AstraZeneca (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Lilly (Inst); Merck (Inst); Nutide (Inst); Ono Pharmaceutical (Inst); Roche (Inst); Sierra Oncology (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Thomas Seufferlein
Honoraria - Amgen; Bayer Schering Pharma; Bristol-Myers Squibb; Celgene; Falk Foundation; Merck Serono; Roche; Sanofi; Shire
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Lilly; Merck Serono
Research Funding - Celgene; Sanofi
Travel, Accommodations, Expenses - Bayer Schering Pharma; Bristol-Myers Squibb; Celgene; Merck Serono; Roche; Sanofi; Shire
 
Takuji Okusaka
Honoraria - Abbvie; AstraZeneca Japan; Bayer Yakuhin; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Fujifilm; Lilly Japan; Nobelpharma; Novartis; Ono Pharmaceutical; Pfizer; Shire; Taiho Pharmaceutical; Takara Bio; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Dainippon Sumitomo Pharma; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan; Baxter; Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; NanoCarrier; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Penny Phillips
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene (I)
 
Xuan Liu
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Abbvie; Bristol-Myers Squibb; Celgene
 
Serena K Perna
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Dung T. Le
Honoraria - Merck
Consulting or Advisory Role - Bristol-Myers Squibb; Merck
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Merck